Why In Vitro Biochemical Testing Matters
While physical characteristics confirm that a liposome has been correctly constructed, in vitro biochemical testing demonstrates how it will behave in the human body. Before a premium formulation ever reaches a consumer, these advanced laboratory models replicate the exact physiological gauntlet the liposome must survive. This crucial layer of validation ensures that the active ingredient is protected against premature degradation, bypasses digestive barriers intact, and achieves a targeted but sustained release precisely where the body can utilize it best.
Stability Testing
- Oxidative Stability:
Liposomal formulations, when exposed to oxidative stress, exhibit lower lipid peroxidation, indicating greater protection of the API against oxidative degradation. - Osmotic Stability:
Determines the stability of a liposomal system in solutions of different salt concentrations (hypotonic, isotonic and hypertonic), which mimic different physiological conditions. Consistent release patterns with slight deviation confirm superior liposomal integrity.
In Vitro Release Study
- In simulated Fluid:
Liposomal formulations are assessed using the INFOGEST protocol on in vitro digestion using simulated fluids- SSF (Simulated Salivary Fluid): To study the release pattern in the mouth phase. Important for understanding the release pattern of sublingual formulations.
- SGF (Simulated Gastric Fluid): To study the release pattern in the gastric environment. A lower release indicates greater stability of the liposomal formulation.
- SIF (simulated Intestinal Fluid): To study the release pattern in intestinal fluid. Higher and sustained release of API indicates greater bioavailability over a prolonged period
- In Phosphate Buffer Saline (PBS)- Simulating Blood:
PBS pH 7.4 mimics our systemic circulation. The release pattern of liposomal API indicates its stability in the circulatory system.
Product Specific Study
- Antioxidant Assay:
Liposomal APIs such as vitamin C, ALA show higher free radical scavenging (DPPH & ABTS) activity compared to non-liposomal APIs, indicating improved antioxidant capacity. - Melanogenesis Inhibition Assay:
In vitro enzymatic assay to determine the anti-tyrosinase activity of liposomal L-GSH. - GSH/GSSH determination:
In vitro enzymatic assay using DTNB to determine the stability of L-GSH when exposed to oxidative stress
Product-Specific Testing Includes
Liposomal, nanosomal, micellar & encapsulated systems across pharmaceutical, nutraceutical & cosmeceutical applications.
In vitro assessment including release kinetics, stability studies, antioxidant capacity, permeation behavior and bioaccessibility using scientifically established methodologies.
Product-specific protocols, method optimization & modified experimental models based on product characteristics and intended application.
End-to-end troubleshooting, comparative evaluation & scalable solutions tailored to client requirements.
Analytical Testing Troubleshooting
Assay inconsistency, calibration drift, method sensitivity refined and standardized.
Unexpected burst/low release, membrane interference, protocol conditions optimized.
Franz/dialysis inconsistencies, membrane integrity, sampling and sink conditions corrected.
Oxidation, lipid peroxidation, environmental impact identified and controlled.
Ready to Elevate Your
Formulation Testing?
Partner with LipoEdge's expert scientific team for end-to-end in vitro analytical support — from study design to regulatory submission.
Frequently Asked Questions
In vitro chemical testing generates release, stability, and bioaccessibility data, enabling informed formulation decisions across nutraceutical, pharmaceutical, and cosmeceutical product development pipelines. This reduces development uncertainty, supports faster optimisation of dosage forms, and strengthens technical confidence before scale-up, validation, and regulatory submission stages.
The INFOGEST model simulates human digestion conditions across salivary, gastric, and intestinal phases, enabling realistic evaluation of liposomal stability and release behaviour. It helps predict oral bioavailability, validate formulation performance under physiological conditions, and support scientifically substantiated claims for product positioning and regulatory documentation.
Dialysis and simulated digestion studies quantify controlled release behaviour, enabling clear differentiation between liposomal systems and conventional formulations in performance-driven markets. This supports claims of sustained delivery, improved absorption, and enhanced functionality, strengthening product positioning across competitive nutraceutical and pharmaceutical segments globally.
LipoEdge provides integrated in vitro testing using validated digestion models, diffusion systems, and antioxidant assays to ensure reliable and reproducible analytical outcomes. It enables clients to generate regulatory-aligned data, optimise formulations effectively, and accelerate product development timelines with strong technical and commercial confidence.
LipoEdge combines formulation understanding with analytical expertise, enabling customised study designs tailored to liposomal, nanosomal, and encapsulated delivery systems across applications. This ensures deeper insight into product behaviour, improved interpretation of results, and stronger alignment between laboratory findings and real-world product performance expectations.